<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180684</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-201</org_study_id>
    <nct_id>NCT03180684</nct_id>
  </id_info>
  <brief_title>Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN)</brief_title>
  <official_title>A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of VGX-3100 followed by
      electroporation (EP) with CELLECTRA™ 2000 alone or in combination with imiquimod in
      participants with human papillomavirus HPV-16 and/or HPV-18 related high grade squamous
      intraepithelial lesion (HSIL) of the vulva. In this study, all eligible participants will
      receive four to six doses of VGX-3100 or VGX-3100 administration in combination with
      imiquimod.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples</measure>
    <time_frame>At Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Percentage of Participants with Adverse Events</measure>
    <time_frame>From baseline to Week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Histologic Evidence of Vulvar HSIL</measure>
    <time_frame>At Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples</measure>
    <time_frame>At Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of Vulvar HSIL, No Evidence of Vulvar Low Grade Squamous Intraepithelial Lesions (LSIL) (Vulvar Intraepithelial Neoplasia 1 [VIN1]), and No Evidence of Condyloma on Histology</measure>
    <time_frame>At Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Progression of Vulvar HSIL to Vulvar Cancer</measure>
    <time_frame>From baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction from Baseline in the Cumulative Surface Area of the Acetowhite Vulvar Lesion(s)</measure>
    <time_frame>From baseline to Weeks 48, 74 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations</measure>
    <time_frame>From baseline to Weeks 15, 27, 48, 74 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Interferon-Gamma Response Magnitude</measure>
    <time_frame>From baseline to Weeks 15, 27, 48, 74 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Flow Cytometry Response Magnitude</measure>
    <time_frame>At baseline and Week 27</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)</condition>
  <condition>Vulvar Dysplasia</condition>
  <condition>Vulvar Intraepithelial Neoplasia (VIN)</condition>
  <condition>VIN2</condition>
  <condition>VIN3</condition>
  <condition>Pre-cancerous Lesions of the Vulva</condition>
  <condition>Human Papillomavirus (HPV)</condition>
  <arm_group>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular (IM) injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VGX-3100 + EP + Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24. In addition, participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VGX-3100</intervention_name>
    <description>One milliliter (1 mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24. A fifth dose and sixth dose of six mg VGX-3100 may be administered IM with EP per the judgment of the Investigator.</description>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
    <arm_group_label>VGX-3100 + EP + Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod 5% cream</intervention_name>
    <description>Participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.</description>
    <arm_group_label>VGX-3100 + EP + Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CELLECTRA™ 2000</intervention_name>
    <description>IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 2000 device.</description>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
    <arm_group_label>VGX-3100 + EP + Imiquimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 and above;

          -  Have high grade squamous intraepithelial lesion (HSIL) of the vulva caused by HPV
             types 16 or 18 confirmed at screening visit;

        Exclusion Criteria:

          -  Untreated microinvasive or invasive cancer;

          -  Biopsy-proven vaginal intraepithelial neoplasia (VAIN), anal intraepithelial neoplasia
             (AIN), or cervical intraepithelial neoplasia (CIN) and not undergoing medical care
             and/or treatment;

          -  Biopsy-proven differentiated VIN;

          -  Treatment for genital warts within 4 weeks prior to screening;

          -  Any previous treatment for vulvar HSIL within 4 weeks prior to screening;

          -  Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream;

          -  Pregnant, breastfeeding or considering becoming pregnant within 6 months following the
             last dose of investigational product;

          -  Immunosuppression as a result of underlying illness or treatment;

          -  Significant acute or chronic medical illness.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ShuPing Yang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inovio Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inovio Call Center</last_name>
    <phone>(267) 440-4237</phone>
    <email>clinical.trials@inovio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jupiter Medical Center</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deia Wilkes</last_name>
      <phone>561-263-5768</phone>
      <email>Deia.Wilkes@jupitermed.com</email>
    </contact>
    <investigator>
      <last_name>Donna Pinelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Goebel</last_name>
      <phone>706-721-2535</phone>
      <email>agoebel@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Daron Ferris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith Dybinski</last_name>
      <phone>312-942-7254</phone>
      <email>judithmdybinski@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Summer Dewdney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital and Health Centers Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Moore</last_name>
      <phone>317-528-2555</phone>
      <email>david.moore@franciscanalliance.org</email>
    </contact>
    <contact_backup>
      <last_name>Cindy Davis</last_name>
      <phone>317-528-7823</phone>
      <email>cynthia.davis3@franciscanalliance.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Moore</last_name>
      <phone>913-588-6287</phone>
      <email>jmoore20@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Ault</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>207-396-8670</phone>
      <email>clinicalresearch@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Darus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Hayden</last_name>
      <phone>734-936-8349</phone>
      <email>jhayden@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Opipari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Wright Pelletier</last_name>
      <phone>269-372-7800</phone>
      <email>lwpelletier@beyerresearch.com</email>
    </contact>
    <investigator>
      <last_name>Roger Beyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Dominic Gynecologic Oncology</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Outlaw</last_name>
      <phone>601-200-4974</phone>
      <email>routlaw@stdom.com</email>
    </contact>
    <investigator>
      <last_name>D. Paul Seago</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alison Pierce</last_name>
      <phone>605-232-9000</phone>
      <email>apierce@mcrmed.com</email>
    </contact>
    <investigator>
      <last_name>Keith Vrbicky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers New Jersey</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Randall Teeter</last_name>
      <phone>973-972-8367</phone>
      <email>randall.teeter@njms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Einstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Hudson</last_name>
      <phone>718-405-8214</phone>
      <email>MEHUDSON@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Akiva Novetsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reena Vattakalam</last_name>
      <phone>212-342-6895</phone>
      <email>rmv2110@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ana Tergas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Parker</last_name>
      <phone>336-354-1076</phone>
      <email>lauren.jones@unifiedhc.com</email>
    </contact>
    <investigator>
      <last_name>Robert Parker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complete HealthCare for Women, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudha Suthanthira</last_name>
      <phone>614-682-5182</phone>
      <email>sutha@drsamuel.org</email>
    </contact>
    <investigator>
      <last_name>Samuel Milroy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Medical Group RC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Trynisha Cheadle</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>46205</phone_ext>
      <email>trynisha-cheadle@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Yebernetsky</last_name>
      <phone>412-641-3578</phone>
      <email>yebernetskyml@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Edwards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chattanooga's Program in Women's Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Donelson</last_name>
      <phone>423-266-3636</phone>
      <email>Kimberly.Donelson@erlanger.org</email>
    </contact>
    <investigator>
      <last_name>Stephen DePasquale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edwina McNeil-Siman</last_name>
      <phone>615-343-9933</phone>
      <email>Edwina.o.mcneill-simaan@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Alvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiana Christian</last_name>
      <phone>414-805-4763</phone>
      <email>qchristian@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>William Bradley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puerto Rico Clinical &amp; Translational Research Consortium University District Hospital, First Floor Medical Center</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina Romaguera</last_name>
      <phone>787-245-8082</phone>
      <email>josefina.romaguera@upr.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janice Diaz</last_name>
      <phone>787-759-0306</phone>
      <email>janice.diaz2@upr.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Josefina Romaguera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV-16</keyword>
  <keyword>HPV-18</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

